Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Vitamin > Vitamin K

Vitamin K

Vitamin K is a fat-soluble vitamin essential for blood clotting and bone metabolism.
It exists in several forms, including phylloquinone (Vitamin K1) and menaquinones (Vitamin K2).
Vitamin K plays a crucial role in the activation of blood clotting factors and regulates calcium deposition in bones and soft tissues.
Deficiency can lead to bleeding disorders and osteoporosis.
Explore the latest research on Vitamin K with PubCompare.ai's AI-driven platform, which helps optimize protocols and products for your studies.
Leverage intelligent comparison tools to unlock the full potentital of Vitamin K and enhance the reproducibility and accuracy of your work.

Most cited protocols related to «Vitamin K»

1
Warfarin Pharmacogenetics Consortium Protocol
Cited 51 times
The International Warfarin Pharmacogenetics Consortium comprises 21 research groups from 9 countries and 4 continents. The research groups contributed clinical and genetic data for a total of 5700 patients who were treated with warfarin. These data were curated (i.e., collected, formatted, and subjected to quality control) by staff at the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB, www.pharmgkb.org) and by members of the consortium. The cohort whose data were analyzed for this study included the subgroup of 5052 patients who had a target international normalized ratio (INR) of 2 to 3. The requirement for informed consent was waived because consent had been obtained previously by each participating center, and only de-identified data were used in the study.
We collected data on clinical factors that have previously been associated with warfarin therapy and that were available from the information received from all or most sites. These data included information on demographic characteristics, the primary indication for warfarin treatment, the stable therapeutic dose of warfarin, the treatment INR (the INR achieved with a stable warfarin dose), the target INR (the desired INR), the use of concomitant medications (grouped according to those that increase and those that decrease the INR), and the presence of genotype variants of CYP2C9 (*1, *2 and *3) and VKORC1 (at least one of seven single nucleotide polymorphisms [SNPs] in linkage disequilibrium11 (link)), as detailed in Section 1 in Supplementary Appendix 1, available with the full text of this article at NEJM.org. Information on race or ethnic group was reported by the patient or determined by the local investigator. Several potentially important variables (e.g., vitamin K intake and smoking status) were not consistently available and thus were not included. Data on adverse events such as thromboembolic events or bleeding or the need for repeated measurements of the INR before a stable dose was achieved were not available for this study. The outcome variable was the stable therapeutic dose of warfarin, defined as the steady-state dose that led to stable anticoagulation levels. Although the centers used different definitions for steady-state dose, most centers required stable levels of anticoagulation (i.e., INR) over a period during which the dose of warfarin was stable (Section 2 in Supplementary Appendix 1).
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. (2009). The New England journal of medicine, 360(8), 753-764.
Publication 2009
Ethnicity Genotype International Normalized Ratio Patients Pharmaceutical Preparations Single Nucleotide Polymorphism Therapeutics Thromboembolism Vitamin K Warfarin
2
Quantifying Gut Microbiome Depletion
Cited 36 times
Day 13 and day 24 of the antibiotic treatment mice were fixed to defecate directly into a pre-weighted 2 ml capped microtube (Sarstedt, Nümbrect, Germany) prefilled with 1 ml sterile ice-cold phosphate-buffered saline (PBS). Tubes with fecal pellets were kept on ice, weighed and the weight of the pellets calculated (median 46 mg, range 17–120). Fecal pellets were resuspended in the 1 ml PBS by vortexing and by bashing with a sterile bacteriological loop. The fecal suspension was then plated on blood agar, anaerobic blood agar (hemin – vitamin K agar), and yeast agar (Sabouraud agar) in doubles with 100 µl suspension on each plate. Blood agar and Sabouraud agar plates were incubated aerobically at 37°C with 5% CO2 for 72 hours, while anaerobic blood agar plates were incubated at 37°C in anaerobic conditions for 96 hours. At the end of incubation the numbers of colonies on the plates were counted and the number of bacteria per mg of feces calculated. Evaluation of cultivated agar plates was performed by an experienced bacteriologist (P.G.) The detection limit of the assay was defined as 1 cfu/mg feces. Only mice successfully depleted (<1 cfu/mg feces) were included in phenotypic and gene expression analyses.
As a positive control for the depletion verification assay, and to enumerate cultivable microbes with the fecal collection procedure, fecal pellets from untreated mice were collected with the above described procedure. Serial dilutions made in sterile PBS and suitable dilutions were plated on selective media for intestinal Gram negative rods, enterococci, anaerobic Gram negative rods (Bacteroides spp), Clostridium spp, Lactobacillus spp and Bifidobacterium spp. The aerobic agar plates were incubated in 37°C with 5% CO2 for 48 hours while anaerobic agar plates were incubated in 37°C for 48 hours. After incubation the numbers of colonies on the plates were counted and the number of bacteria per mg of feces was calculated.
Reikvam D.H., Erofeev A., Sandvik A., Grcic V., Jahnsen F.L., Gaustad P., McCoy K.D., Macpherson A.J., Meza-Zepeda L.A, & Johansen F.E. (2011). Depletion of Murine Intestinal Microbiota: Effects on Gut Mucosa and Epithelial Gene Expression. PLoS ONE, 6(3), e17996.
Full text: Click here
Publication 2011
Agar Antibiotics Bacteria Bacteria, Aerobic Bacteroides Bifidobacterium Biological Assay BLOOD Clostridium Common Cold Enterococcus Feces Gene Expression Profiling Hemin Intestines Lactobacillus Mice, House Pellets, Drug Phenotype Phosphates Rod Photoreceptors Saline Solution Sterility, Reproductive Technique, Dilution Vitamin K Yeast, Dried
3
Thromboembolism Risk in Non-Valvular Atrial Fibrillation
Cited 24 times
In patients discharged with non-valvular atrial fibrillation who were not receiving treatment with vitamin K antagonists or heparins, we estimated event rates for thromboembolism and death for the various CHADS2 and CHA2DS2-VASc scores and for the specific covariate combinations forming the scores of 1 or 2. We estimated the risk of thromboembolism by using Cox proportional hazard regression models. In the Cox models, we analysed the risk associated with all possible risk factor combinations for CHADS2 score=1 (four combinations) and CHADS2 score=2 (seven combinations); we used CHADS2 score=0 as the reference. In the same manner, other Cox models analysed the risk associated with all possible risk factor combinations for CHA2DS2-VASc score=1 (six combinations) and CHA2DS2-VASc score=2 (17 combinations), with CHA2DS2-VASc score=0 used as the reference. We did all analyses for one, five, and 10 years of follow-up. In additional Cox regression models, we included concomitant treatment with antiplatelet drugs (that is, primary acetylsalicylic acid, clopidogrel, and dipyridamole), to adjust for this potential confounder. We also did sensitivity analyses by not including pulmonary embolism as an outcome.
We used C statistics estimated from Cox regression models to assess the predictive capability of CHADS2 and CHA2DS2-VASc for thromboembolism, using the method described by Liu and colleagues.24 C statistics give a measure of how well the risk prediction scheme identifies patients who will have a future event. For estimating C statistics, we analysed CHADS2 and CHA2DS2-VASc as risk scores (0-6 and 0-9) and as risk groups (low, intermediate, and high). We also evaluated the scores both as categorical and as continuous covariates. We constructed survival curves, based on Kaplan-Meier estimates of the probability of remaining free of thromboembolism with a score of 0 and 1, for the two risk stratification schemes. We considered a two sided P value <0.05 to be statistically significant. In all Cox models, the model assumptions (that is, proportional hazards, linearity of continuous covariates, and lack of interactions) were found to be valid. We used SAS statistical software version 9.1 and Stata statistical software version 11.0 for the analyses.
Olesen J.B., Lip G.Y., Hansen M.L., Hansen P.R., Tolstrup J.S., Lindhardsen J., Selmer C., Ahlehoff O., Olsen A.M., Gislason G.H, & Torp-Pedersen C. (2011). Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. The BMJ, 342, d124.
Publication 2011
antagonists Antiplatelet Agents Aspirin Atrial Fibrillation Clopidogrel Dipyridamole Heparin Hypersensitivity Patients Population at Risk Pulmonary Embolism Thromboembolism Vitamin K
4
Warfarin Pharmacogenetic Dosing Validation
Cited 13 times
After Institutional Review Board approval at the participating sites, we obtained clinical and genetic data on 1213 patients in 3 continents: University of Alabama (N=62), Hospital for Special Surgery (N=11), Kaiser Permanente Colorado (N=30), University of Liverpool (N=149), Marshfield Clinic (N=147), Washington University in St. Louis School of Medicine (N=264), Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (N=29), University of Pennsylvania (N=86), Uppsala University, Uppsala, Sweden (N=2), Intermountain Medical Center (N=155), Karolinska Institutet, Stockholm, Sweden (N=278). Patients were excluded if they did not achieve a therapeutic dose (defined below), if an INR on day 4 or 5 was not available, if their baseline (pre-warfarin) INR was above 1.4, if they were not genotyped for CYP2C9*2, CYP2C9*3 or VKORC1, or if they were prescribed fresh frozen plasma or vitamin K prior to their INR measurement. We randomly sampled 80% of the data for derivation, setting aside 20% for internal validation (Table 1). Dosing protocols varied among sites, with some participants (31%) being initiated on warfarin therapy using pharmacogenetic dosing algorithms.(29 (link), 30 (link), 46 (link)) However, stratifying by whether or not sites used a pharmacogenetic dosing protocol did not improve predictive accuracy. After development and internal validation, we studied 584 patients from 4 additional sites to validate the final algorithm (which was derived from combining the derivation and internal validation cohorts): Vanderbilt University (N=132), Inje University College of Medicine, South Korea (N=139), and University of Utah Hospital (N=117). The University of Liverpool also genotyped additional patients for external validation (N=196). Data from these 584 additional patients comprised the external validation cohort. Some of the data in the present analysis, were used for other pharmacogenetic analyses (8 (link), 9 (link), 16 (link), 29 (link), 30 (link), 31 (link), 51 (link), 52 (link), 53 (link)).
Lenzini P., Wadelius M., Kimmel S., Anderson J.L., Jorgensen A.L., Pirmohamed M., Caldwell M.D., Limdi N., Burmester J.K., Dowd M.B., Angchaisuksiri P., Bass A.R., Chen J., Eriksson N., Rane A., Lindh J.D., Carlquist J.F., Horne B.D., Grice G., Milligan P.E., Eby C., Shin J., Kim H., Kurnik D., Stein C.M., McMillin G., Pendleton R.C., Berg R.L., Deloukas P, & Gage B.F. (2010). Integration of genetic, clinical, and INR data to refine warfarin dosing. Clinical pharmacology and therapeutics, 87(5), 572-578.
Publication 2010
Ethics Committees, Research Operative Surgical Procedures Patients Pharmaceutical Preparations Pharmacogenomic Analysis Plasma, Fresh Frozen Therapeutics Vitamin K Warfarin
5
Identifying Atrial Fibrillation Patients
Cited 10 times
From the national patient registry, we identified all patients with non-valvular atrial fibrillation or atrial flutter in the period 1997-2006. We defined non-valvular atrial fibrillation by a discharge diagnosis of atrial fibrillation or atrial flutter (diagnosis code I48), no previous diagnoses of mitral or aortic valve disease (394-396, 4240, 4241, I05, I06, I34, I35), and no mitral or aortic valve surgery (surgical procedure codes KFK, KFM, KFP), as done previously.17 (link) Because drug treatment may be changed or intensified in relation to hospital admission, we started follow-up seven days after discharge. We excluded patients if they died or had a thromboembolism in this seven day quarantine period. We identified drug treatment status from prescription claims from 180 days before discharge to seven days after discharge, and we excluded patients if they had received vitamin K antagonists (medicine code B01AA) or heparins (B01AB) (fig 1). We censored patients at time of death or at the end of the follow-up periods—that is, at one, five, and 10 years.
Olesen J.B., Lip G.Y., Hansen M.L., Hansen P.R., Tolstrup J.S., Lindhardsen J., Selmer C., Ahlehoff O., Olsen A.M., Gislason G.H, & Torp-Pedersen C. (2011). Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. The BMJ, 342, d124.
Publication 2011
antagonists Atrial Fibrillation Atrial Flutter Diagnosis Heparin Operative Surgical Procedures Patient Discharge Patients Pharmaceutical Preparations Prescription Drugs Quarantine Thromboembolism Valve Disorder, Aortic Valves, Aortic Vitamin K

Most recents protocols related to «Vitamin K»

1
Silicic Acid and Mineral Supplementation Protocol
Not available on PMC !

Example 6

    • Daily oral administration of 5 mg of bioavailable silicic acid in the form of choline-stabilized orthosilicic acid (ch-OSA®), wherein silicic acid is stabilized with choline chloride, for instance in the form of a capsule;
    • Daily administration of 1000 mg calcium, 6 microgram vitamin D, 50 microgram vitamin K, preferably in two formulations, such as tablets;
    • Daily administration of 200 mg vitamin C, 100 microgram selenium, 10 mg zinc, 1 mg copper, 0.5 mg boron, 200 mg magnesium, for instance in the form of a single formulation, such as a tablet.

    • 6 months oral administration of 10 mg of a bioavailable silicon compound per day, which bioavailable silicon compound is in the form of choline-stabilized orthosilicic acid (ch-OSA®), wherein silicic acid is stabilized with choline chloride; 10 mg bioavailable silicon is preferably administered as two dosage units, each containing 5 mg bioavailable silicon, for instance as a tablet;
    • mouth rinsing with chlorhexidine 1% solution twice daily during 4 weeks.

It is herein preferable, that the administration of the bioavailable silicic acid and the mouth rinsing start simultaneously.

US11878031B2. Silicic acids for use in the treatment of periodontitis (2024-01-23). Bio Minerals N.V. [BE]. Inventors: Mario Remi Yvonne Calomme [BE], Kathleen Jozef Ingrid Suzanne Van Hoof [BE].
Full text: Click here
Patent 2024
Acids Administration, Oral Ascorbic Acid Boron Calcium, Dietary Capsule Chlorhexidine Choline Choline Chloride Copper Magnesium Periodontitis Selenium Silicic acid Silicon Tablet Vitamin D Vitamin K Zinc
2
Silicic Acid and Bone Health Supplement Protocol
Not available on PMC !

Example 11

    • 12 months oral administration of 10 mg of bioavailable silicic acid per day in the form of choline-stabilized orthosilicic acid (ch-OSA®), wherein silicic acid is stabilized with choline chloride, preferably in the form of two dosage units, such as capsules.
    • Daily administration of 1000 mg calcium, 6 microgram vitamin D, 50 microgram vitamin K, preferably in the form of two dosage units, such as tablets.
    • Daily administration of 200 mg vitamin C, 100 microgram selenium, 10 mg zinc, 1 mg copper, 0.5 mg boron, 200 mg magnesium, preferably in the form of a table.
    • irrigating the periodontal pockets and cleaning the implants with chlorhexidine 1% solution
    • mouth rinsing with chlorhexidine 1% solution twice daily during 4 weeks.

US11878031B2. Silicic acids for use in the treatment of periodontitis (2024-01-23). Bio Minerals N.V. [BE]. Inventors: Mario Remi Yvonne Calomme [BE], Kathleen Jozef Ingrid Suzanne Van Hoof [BE].
Full text: Click here
Patent 2024
Acids Ascorbic Acid Boron Calcium, Dietary Capsule Chlorhexidine Choline Choline Chloride Copper Dosage Forms Ergocalciferol Magnesium Patient Care Management Peri-Implantitis Periodontal Pocket Selenium Silicic acid Vitamin K Zinc
3
Micronutrient GWAS Synthesis and Analysis
We searched for published GWASs evaluating individuals of European ancestry on the GWAS Catalog and PubMed (the last search was performed in May 2022). We did not find any GWAS conducted for vitamins B1, B2, B3, B5, B7, sulfur, iodine, chloride, and fluoride. The GWASs conducted for vitamin K, potassium, sodium, cobalt, chromium, and molybdenum were excluded because of no significant genome-wide results [8 (link), 18 (link), 19 (link)]. In total, fourteen micronutrients of potential interest were identified: calcium [5 (link)], copper [6 (link)], iron [7 (link)], magnesium [8 (link)], selenium [6 (link)], zinc [6 (link)], beta-carotene [9 (link)], folate [10 (link)], vitamin A [11 (link)], vitamin B6 [12 (link)], vitamin B12 [10 (link)], vitamin C [13 (link)], vitamin D [14 (link)], and vitamin E [15 (link)] (Additional file 2: Additional Text) [5 (link)–15 (link), 20 , 21 (link)]. For copper, we also identified a more recent and larger GWAS by Jäger et al. [20 ], but given that this study reported Z-scores and not beta-coefficients, we used the study by Evans et al. [6 (link)] in order to improve interpretability. However, the genetic instruments from the GWAS by Jäger et al. [20 ] were used in secondary analyses. Vitamin A and vitamin E were excluded because those GWASs were adjusted for body mass index (BMI) [22 (link)] which might introduce collider bias if the genetic instruments of the exposure of interest also have an effect on BMI [23 (link)].
For the main MR analysis, we included independent SNPs (r2 < 0.001 within 10,000-kb windows), strongly associated (P ≤ 5E−08) with the blood level of each micronutrient.
Flatby H.M., Ravi A., Damås J.K., Solligård E, & Rogne T. (2023). Circulating levels of micronutrients and risk of infections: a Mendelian randomization study. BMC Medicine, 21, 84.
Full text: Click here
Publication 2023
Ascorbic Acid beta Carotene BLOOD Calcium Chlorides Chromium Cobalamins Cobalt Copper Ergocalciferol Europeans Fluorides Folate Genome Genome-Wide Association Study Index, Body Mass Iodine Iron Magnesium Micronutrients Molybdenum Potassium Reproduction Selenium Single Nucleotide Polymorphism Sodium Sulfur Thiamine Vitamin A Vitamin B6 Vitamin E Vitamin K Zinc
4
Vitamins and Animal Nutrition
Most fat-soluble vitamins are not easily eliminated from the body and are instead retained in the liver and adipose tissues alongside fat. On the other hand, the body tends to keep a far smaller quantity of water-soluble vitamins than it does fat-soluble vitamins. The majority of vitamins found in livestock and human diets are produced either by plants or microorganisms. Some animal cells can synthesize vitamins like vitamin D, niacin, and ascorbate, and convert pro-vitamins to the active form (McDowell, 2008 ). Additionally, commensal microbes in the digestive tracts of both ruminants and non-ruminants have the potential to operate as a source of some vitamins, including vitamin K and the water-soluble B-complex vitamins (McDowell, 2008 ). Regarding human nutrition, meat has long been acknowledged as a reliable source of B vitamins (Obeid et al., 2019 (link)).
Haque A., Ahmad S., Azad Z.R., Adnan M, & Ashraf S.A. (2023). Incorporating dietary fiber from fruit and vegetable waste in meat products: a systematic approach for sustainable meat processing and improving the functional, nutritional and health attributes. PeerJ, 11, e14977.
Full text: Click here
Publication 2023
Animals Cells Diet Ergocalciferol Gastrointestinal Tract Homo sapiens Human Body Liver Livestock Meat Niacin Plants Ruminants Vitamin A Vitamin B Complex Vitamin K Vitamins
5
Extremely Premature Baboon Delivery and Surfactant Treatment
Pregnant baboons received general anesthesia and fetuses were delivered by primary caesarean section. Extremely premature-born animals (Table 2) were weighed and placed in plastic wrap to prevent hypothermia. Baboons then received intramuscular ketamine (10 mg/kg; Putney), Vitamin K (0.5 mg; Hospira). We then intubated the animals orotracheally, using uncuffed endotracheal tubes (Vygon) and slowly instilled 120 mg Poractant alfa (Chiesi Farmaceutici) via the lateral port of the tube. During this procedure, animals were started on pressure-controlled, continuous mandatory ventilation (PC-CMV) with a rate of 40 min−1, peak inspiratory pressure (PIP) of 30 cmH2O, positive end expiratory pressure (PEEP) of 5 cmH2O and a fraction of inspired oxygen (FiO2) of 0.4 utilizing a VIP Gold Bird (CareFusion) respirator. Respiratory support was continuously adapted, based on heart rate and pre-ductal peripheral oxygen saturation (SPO2). A 21 G umbilical arterial catheter (UAC; Covidien/Medtronic) and a 24 G peripheral inserted central venous catheter (PICC; Vygon) were placed as well as an orogastric tube. The mothers were closely monitored by the attending veterinarian staff after surgical repair of incisions and returned to their colonies within 2 to 4 weeks after the surgery.
Möbius M.A., Seidner S.R., McCurnin D.C., Menschner L., Fürböter-Behnert I., Schönfeld J., Marzahn J., Freund D., Münch N., Hering S., Mustafa S.B., Anzueto D.G., Winter L.A., Blanco C.L., Hanes M.A., Rüdiger M, & Thébaud B. (2023). Prophylactic Administration of Mesenchymal Stromal Cells Does Not Prevent Arrested Lung Development in Extremely Premature-Born Non-Human Primates. Stem Cells Translational Medicine, 12(2), 97-111.
Publication 2023
Animals Arteries Aves Catheters Cesarean Section Childbirth Fetus General Anesthesia Gold Ketamine Mechanical Ventilator Mothers Operative Surgical Procedures Oxygen Papio poractant alfa Positive End-Expiratory Pressure Premature Birth Pressure Rate, Heart Respiratory Rate Saturation of Peripheral Oxygen Surgical Wound Umbilicus Venous Catheter, Central Veterinarian Vitamin K

Top products related to «Vitamin K»

1
Vitamin k by Merck Group
Sourced in United States, United Kingdom, Germany
Vitamin K is a lab equipment product that plays a crucial role in the regulation of blood clotting. It is a fat-soluble vitamin that serves as a cofactor for enzymes involved in the production of clotting factors, enabling the formation of fibrin clots. The product is used in various laboratory settings to study and measure the blood's coagulation properties.
2
Hemin by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, Japan, Austria, Sao Tome and Principe, Brazil, Italy, Canada, Norway, Sweden, Israel, Belgium, Poland, Cameroon, Netherlands, Switzerland, India
Hemin is a laboratory product that serves as a source of heme, the iron-containing cofactor found in various hemoproteins. It is commonly used in biochemical and cell culture applications for its role in heme-dependent processes.
3
L cysteine by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, France, Canada, Poland, Sao Tome and Principe, Norway, Japan, Sweden, China, Israel, Macao, Switzerland, Spain, Austria, Brazil
L-cysteine is an amino acid that serves as a key component in the manufacturing of various laboratory reagents and equipment. It functions as a building block for proteins and plays a crucial role in the formulation of buffers, cell culture media, and other essential laboratory solutions.
4
Bhi broth by BD
Sourced in United States, France, Japan
BHI broth is a general-purpose microbiological growth medium. It is composed of a mixture of nutrients designed to support the growth of a wide range of microorganisms, including bacteria, yeast, and fungi. The broth provides essential nutrients and growth factors required for microbial proliferation.
5
Anaerobic chamber by Don Whitley Scientific
Sourced in United Kingdom, United States
The Anaerobic Chamber is a self-contained, controlled environment designed to maintain an anaerobic (oxygen-free) atmosphere. It serves as a workspace for conducting experiments and procedures that require an anaerobic condition.
6
Resazurin by Merck Group
Sourced in United States, Germany, United Kingdom, Portugal, Australia, Italy, Canada, India, Brazil, France, Belgium, Poland, Sweden, Spain, China, Netherlands
Resazurin is a redox-sensitive dye that can be used as a non-toxic indicator in cell viability and proliferation assays. It undergoes a color change from blue to pink upon reduction, which can be measured using spectrophotometric or fluorometric methods.
7
Yeast extract by Thermo Fisher Scientific
Sourced in United Kingdom, United States, China, Germany, Italy, Belgium, Canada, Sweden, France, Australia, Spain, Poland, Denmark, Brazil
Yeast extract is a light-colored, water-soluble powder that is derived from the autolysis of baker's yeast. It serves as a nutrient source, providing a complex mixture of amino acids, vitamins, and other growth factors to support the cultivation of microbial cultures in various scientific and industrial applications.
8
Yeast extract by BD
Sourced in United States, Japan, Germany, United Kingdom, France, India, Poland, Mexico, Australia, Italy, Canada
Yeast extract is a powder or paste derived from the autolysis of yeast cells. It contains a variety of amino acids, vitamins, and other nutrients that can support the growth and propagation of microorganisms in laboratory settings.
9
Yeast extract by Merck Group
Sourced in United States, Germany, United Kingdom, Spain, China, Australia, France, India, Switzerland, Italy, Poland, Sao Tome and Principe, Sweden
Yeast extract is a versatile laboratory product derived from the autolysis of baker's yeast. It contains a rich source of amino acids, vitamins, and other essential nutrients that are beneficial for the cultivation and growth of microorganisms. Yeast extract is commonly used as a nutrient supplement in microbial culture media for a variety of applications, including fermentation processes, cell culture, and the production of various biological products.
10
Vitamin k by Carl Roth
Sourced in Germany
Vitamin K is a fat-soluble vitamin essential for blood clotting. It plays a crucial role in the production of prothrombin, a protein required for normal blood coagulation.

More about "Vitamin K"

Vitamin K is a crucial micronutrient for the body, playing a vital role in blood coagulation and bone metabolism.
It comes in various forms, including phylloquinone (K1) and menaquinones (K2).
This fat-soluble vitamin is essential for activating blood clotting factors and regulating calcium deposition in bones and soft tissues.
A deficiency in Vitamin K can lead to bleeding disorders and osteoporosis.
Researchers are continuously exploring the potential of Vitamin K through studies on its diverse functions and applications.
PubCompare.ai's AI-driven platform can help optimize your research protocols and products related to Vitamin K, Hemin, L-cysteine, BHI broth, Anaerobic chamber, Resazurin, and Yeast extract.
Leverage intelligent comparison tools to enhance the reproducibility and accuracy of your work, unlocking the full potential of this versatile nutrient.
Explore the latest preprints, patents, and published literature to stay at the forefront of Vitamin K research and elevate your scientific endeavors.